| ATG9A Protein | |
|---|---|
| Protein Name | Autophagy-related protein 9A |
| Encoded by | [ATG9A](/genes/atg9a) |
| UniProt | [Q7Z418](https://www.uniprot.org/uniprotkb/Q7Z418/entry) |
| Localization | Trans-Golgi network, endosomes, plasma membrane, autophagosomes |
| Protein Class | Multi-pass transmembrane autophagy protein |
| Major Pathway | [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway) |
ATG9A (Autophagy-Related Protein 9A) is the only multi-spanning transmembrane protein in the core autophagy machinery, playing an essential role in autophagosome biogenesis by providing membrane lipids and serving as a membrane source for phagophore expansion. Unlike other ATG proteins that are soluble or peripherally associated with membranes, ATG9A is an integral membrane protein that spans the membrane multiple times, uniquely positioning it to serve as a membrane source for autophagosome formation[1][2].
The protein cycles between different cellular compartments in a process tightly regulated by the autophagy initiation machinery. During starvation-induced autophagy, ATG9A-containing vesicles are actively recruited to the phagophore assembly site (PAS), where they contribute their membrane to the growing phagophore. This function makes ATG9A essential for autophagosome nucleation and expansion, with knockout or knockdown of ATG9A severely impairing autophagy and leading to accumulation of protein aggregates and damaged organelles[3].
In the nervous system, ATG9A is critical for neuronal homeostasis, as autophagy is essential for clearing misfolded proteins, damaged mitochondria, and other cellular debris. Dysregulation of ATG9A-mediated autophagy has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis[4][5].
ATG9A is a 939-amino acid protein with multiple transmembrane domains:
N-terminal Cytoplasmic Domain (1-200 aa): Contains sorting signals (YXXΦ motifs) and ATG2 interaction motifs that mediate recruitment to autophagy initiation sites.
Transmembrane Regions (200-700 aa): Multiple transmembrane segments (typically 12-15) that anchor the protein in membrane compartments. These regions form the core of the protein and are highly conserved.
C-terminal Cytoplasmic Domain (700-939 aa): Contains regulatory sites including phosphorylation residues and additional sorting signals. This region modulates protein localization and interactions.
The structure of ATG9A (PDB: 6J5N) reveals a unique fold that allows it to:
ATG9A plays multiple essential roles in autophagosome formation[3:1]:
Membrane Source: Provides lipids from donor compartments (TGN, endosomes, plasma membrane) to the expanding phagophore.
Vesicle Cycling: ATG9A transits between the trans-Golgi network, endosomes, and plasma membrane in a regulated manner.
Lipid Transfer: Through interactions with ATG2, ATG9A facilitates direct lipid transfer from the ER to forming autophagosomes.
Autophagosome Formation: Essential for nucleation and expansion of the phagophore.
ATG9A participates in membrane trafficking pathways:
Trans-Golgi Network Dynamics: ATG9A cycles through the TGN, contributing membrane to various cellular compartments.
Endosomal Function: ATG9A localizes to endosomes and participates in endosomal maturation.
Plasma Membrane Recycling: ATG9A can be found at the plasma membrane, where it may be internalized during autophagy initiation.
ATG9A is regulated at multiple levels:
Phosphorylation: ULK1 phosphorylates ATG9A during autophagy initiation, promoting its recruitment to the PAS.
Lipid Binding: Interactions with phosphoinositides regulate membrane targeting.
Protein Interactions: ATG2, WIPI proteins, and other ATG proteins regulate ATG9A function.
ATG9A dysfunction contributes to AD pathogenesis through multiple mechanisms[6][4:1]:
Amyloid-Beta Metabolism: Impaired autophagy leads to altered amyloid-β processing and accumulation. ATG9A deficiency results in reduced clearance of Aβ species.
Tau Pathology: Dysregulated autophagy affects tau clearance, contributing to neurofibrillary tangle formation[5:1].
Neuronal Survival: Loss of autophagy leads to accumulation of damaged organelles and protein aggregates, contributing to neurodegeneration.
Synaptic Dysfunction: ATG9A deficiency impairs synaptic autophagy, contributing to early synaptic loss.
Endolysosomal Dysfunction: ATG9A affects lysosomal function and trafficking.
ATG9A is critical in PD through several mechanisms[7][8]:
α-Synuclein Clearance: Autophagy-mediated degradation of α-synuclein is the primary clearance pathway for this protein. ATG9A dysfunction leads to accumulation of toxic α-synuclein species.
Mitophagy: PINK1/Parkin-mediated mitochondrial quality control depends on functional autophagy. ATG9A deficiency impairs mitophagy and leads to accumulation of damaged mitochondria.
Dopaminergic Neuron Survival: ATG9A is essential for the survival of dopaminergic neurons in the substantia nigra.
LRRK2 Interaction: ATG9A has been linked to LRRK2 pathogenic variants, with some LRRK2 mutations affecting autophagy through ATG9A.
In ALS:
Protein Aggregate Clearance: ATG9A-mediated autophagy clears TDP-43 aggregates, a hallmark of ALS pathology.
Motor Neuron Survival: ATG9A is critical for motor neuron health, with deficiency leading to progressive motor neuron degeneration.
Axonal Homeostasis: ATG9A maintains axonal integrity through autophagy-mediated clearance of axonal debris.
ER Stress: ATG9A dysfunction contributes to ER stress, a common feature of ALS pathogenesis[9].
In HD:
Mutant Huntingtin Clearance: Autophagy clears toxic huntingtin protein aggregates. ATG9A deficiency leads to accumulation of mutant huntingtin.
Neuronal Dysfunction: Loss of ATG9A function exacerbates pathology and accelerates disease progression.
Vesicle Trafficking: Altered membrane dynamics affect neuronal function.
Autophagy Enhancers: Compounds that boost ATG9A-mediated autophagy (e.g., rapamycin, trehalose)
mTOR Inhibitors: Rapamycin and analogs enhance autophagy through mTOR inhibition
Small Molecule Modulators: Direct ATG9A-targeting compounds in development
Gene Therapy: Viral vector delivery of ATG9A to enhance autophagy[10]
ATG9A interacts with key autophagy proteins:
| Protein | Interaction Type | Functional Significance |
|---|---|---|
| ATG2A/B | Direct binding | Lipid transfer from ER |
| WIPI1/2/3/4 | Indirect | Phosphatidylinositol 3-phosphate binding |
| ULK1/2 Complex | Direct | Phosphorylation and recruitment |
| ATG14L | Indirect | Autophagosome targeting |
| VPS34/PIK3C3 | Indirect | Lipid kinase complex |
| ATG5 | Indirect | Autophagy conjugation system |
| ATG7 | Indirect | LC3 activation |
Weaver AN, Yang T, Pu J, et al. ATG9A structure and function in autophagy. Autophagy. 2012. ↩︎
Mizushima N, Yoshimori T, Ohsumi Y. Autophagy membrane dynamics. Annu Rev Cell Dev Biol. 2014. ↩︎
Yamaguchi H, Arasaki M, Mizushima N. ATG9A in autophagosome formation. J Cell Biol. 2015. ↩︎ ↩︎
Menzies FM, Fleming A, Rubinsztein DC. Autophagy in neurodegenerative disease. Nat Rev Neurosci. 2016. ↩︎ ↩︎
Song P, Li S, Wu M, et al. ATG9A in tauopathy. Acta Neuropathol Commun. 2019. ↩︎ ↩︎
Tang J, Gu X, Song W, et al. ATG9A dysfunction in Alzheimer's disease. J Alzheimers Dis. 2021. ↩︎
Sakamoto K, Hamasaki M, Kanda A, et al. ATG9A and alpha-synuclein clearance. Autophagy. 2017. ↩︎
Pickles S, Vigié P, Youle RJ. Mitophagy in Parkinson's disease. Curr Biol. 2018. ↩︎
Liu Y, Liu H, Yang J, et al. ATG9A and ER stress in neurodegeneration. Cell Death Dis. 2022. ↩︎
Zhao Y, Liu C, Xin Y, et al. ATG9A gene therapy approaches. Mol Ther Methods Clin Dev. 2022. ↩︎